Atara Biotherapeutics, Inc. (ATRA): debt financing — Atara Bio closes $31M royalty financing liability with HCR Molag Fund

Atara Biotherapeutics, Inc.

Closed $31M royalty financing with HCR Molag Fund on Dec 30, 2022; recorded net of transaction costs.
Financing stems from Purchase and Sale Agreement dated Dec 20, 2022, previously disclosed.
Transaction creates a direct financial obligation under Item 2.03 of Form 8-K.
HCR Molag Fund, L.P. is the counterparty; net proceeds used for general corporate purposes (not specified).

item 2.03 item 1.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Atara Biotherapeutics, Inc. incurred debt of $31,000,000, net of certain transaction costs with HCR Molag Fund, L.P..

Principal: $31,000,000, net of certain transaction costs
Counterparty: HCR Molag Fund, L.P.
Event: incurrence

Exact text from the filing

On December 30, 2022, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), and HCR Molag Fund, L.P., a Delaware limited partnership (“HCR”), closed the transactions contemplated by that certain Purchase and Sale Agreement dated December 20, 2022 by and between the Company and HCR.

View on SEC.gov

223 debt financings filed in the last 30 days. Browse all debt financings →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-003555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.